There is an increasing burden of non-AIDS-defining malignancies (NADMs) in the antiretroviral therapy (ART) era. The recent literature is reviewed with respect to NADM risk, ART use, and immune function.
Introduction
Effective antiretroviral therapy (ART) use has prolonged the lifespan of HIV-infected patients and resulted in dramatic declines in the risk of AIDS clinical events, including AIDS-defining malignancies (ADMs). However, there is a growing concern in the ART era for non-AIDS-defining malignancies (NADMs), given the aging population of HIV-infected patients and the high prevalence of tobacco use, alcohol use and viral coinfections in this population [1] . Thus, many prior studies have focused on changes in risk in the ART era for more common NADMs in HIV patients, namely Hodgkin's lymphoma [2] [3] [4] [5] [6] , lung [2] [3] [4] 7, 8] , and anal [2] [3] [4] [5] 9] cancers, but with mixed results. More recent studies have evaluated malignancy risk with respect to individual ART use, including the effect of specific antiretroviral agents, ART drug classes, or ART duration. Others have evaluated the association of immune function and NADM risk, which may mediate observed relationships of cancer risk and ART use.
We provide here a summary and discussion of the recent published literature regarding malignancy risk, ART use, and immunosuppression. We performed an Englishlanguage MEDLINE search for relevant studies during the period January 2007-July 2008.
Antiretroviral therapy use and the risk of non-AIDS-defining malignancies
The ecologic comparison of cancer incidence before and after the introduction of ART has been the most common method for examining the effect of ART use on cancer risk [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . However, this approach may not accurately reflect the association of ART on cancer incidence as other factors influencing cancer risk may have also changed over time. Furthermore, many patients may not be taking ART in the post-ART era. A few studies earlier in the ART era have examined the effect of individual ART use on cancer risk [2, [17] [18] [19] [20] , though all classified ART use dichotomously as ever or never, and only Clifford et al. [2] examined individual NADMs.
Calendar era trends
There have been substantial declines in the incidence of ADMs in the ART era [5] [6] [10] [11] [12] [13] [14] [15] . Prior studies focusing on NADMs, however, were mixed. Higher incidence in the ART era relative to the pre-ART era has been previously demonstrated for Hodgkin's lymphoma [2, 3, 6, 16] , nonmelanoma skin [5] , lung [3, 7] , anal [5, 9] , kidney [6] and for all NADMs combined [5] . Others demonstrated no calendar era changes for Hodgkin's lymphoma [4, 5] , nonmelanoma skin [2] [3] [4] , anal [2] [3] [4] all NADMs combined [2] [3] [4] 6, 8, 17] , various other individual cancers [2] [3] [4] [5] [6] , and no change [2, 4, 8] or declines for lung cancer [6] .
More recent studies (Table 1) [21 ,22 ,23 ,24 ,25 ,26 , 27 ,28 ,29 ,30] Several of these recent studies determined cancer rates by linking US-based HIV/AIDS and cancer registries [23 ,24 ,27 ] . Major strengths of registry match studies are the population-based design and the large sample sizes. However, a limitation of this study design was the inclusion of AIDS cases only and not HIV-infected persons at earlier stages of disease. The recent cancer registry match study by Engels et al. [23 ] was notable in that both reported HIV and AIDS cases were included. Others have evaluated trends in cancer risk in cohort studies [21 ,22 ,25 ,26 ,28 ,29 ,30,31] , which tend to be smaller in size, but include HIV patients at all stages of disease. Patel et al. [22 ] reported the results of cancer risk using two large cohorts: the Adult and Adolescent Spectrum of Disease Project (n ¼ 47 832) and the HIV Outpatient Study (n ¼ 6948). The strengths of this analysis were the large sample size, the inclusion of HIV patients with any stage of HIV/AIDS, and the ability to evaluate individual risk factors. They found higher risks of several cancers in the ART era (Table 1 ), but only anal cancer increased over time compared with general population rates.
Observed changes over time in risks of individual cancers maybe due to differences in the prevalence of risk factors over time or perhaps increased screening for anal, prostate, or other cancers in HIV-infected patients in recent years. Few studies have evaluated cancer screening practice changes in HIV patients, though Rimland et al. [29 ] noted marked increases in prostate-specific antigen testing in the ART era for HIV-infected US Veterans.
Individual antiretroviral therapy use
Studies comparing cancer rates in the pre and post-ART era may not reflect the true effect of ART use. Thus, recent studies have increasingly focused on individual ART use and cancer risk ( Table 2) [32 -37 ] . In the largest study to date to evaluate the risk of cancers and individual ART use, Piketty et al. [26 ] reported an increased risk for anal cancer with any ART use [hazard ratio ¼ 1.7; 95% confidence interval (CI) 1.1-2.8], but this has not been confirmed by others [22 ,24 ,37 ] . Hessol et al. [24 ] determined that only liver cancer among all cancers studied had a reduced risk with current ART use (hazard ratio ¼ 0.3; 95% CI 0.1-0.9), again a finding not supported by other studies [22 ,35 ] . Patel et al.
[22 ] reported that any ART use was associated with a lower risk of breast (risk ratio ¼ 0.4; P ¼ 0.013), colorectal (risk ratio ¼ 0.5; P ¼ 0.027), and lung (risk ratio ¼ 0.5; P < 0.003) cancers. However, others have not found an association with ART use and these same cancers [24 ,28 ,35 ] . Finally, others have reported that ART use is not associated with skin cancer [ were unique because they reported both calendar era trends and the effect of individual ART use. Cancers associated with ART use and calendar era trends were not the same within each study, indicating that calendar era trends may reflect changes in the epidemiology of cancers, but not necessarily direct effects of individual ART use.
Individual ART medications or therapeutic classes may also have a more direct effect on cancer risk. Early studies in the ART era reported that among Kaposi's sarcoma cases, lesions tended to regress after initiating a protease inhibitor-based ART regimen [38] [39] [40] [41] [42] [43] . Others, however, demonstrated no difference in progression of Kaposi's sarcoma [44, 45] or non-Hodgkin's lymphoma (NHL) [46] comparing protease inhibitor-based and protease inhibitor-sparing regimens. Only one cohort study to date has evaluated individual protease inhibitors, namely nelfinavir and indinavir, on any NADM risk and found no association [34 ] . Experimentally, a beneficial effect for protease inhibitors has been demonstrated for Kaposi's sarcoma [47] [48] [49] , and for ritonavir [50] , saquinavir [50, 51] , indinavir [50] , nelfinavir [52] [53] [54] [55] , and atazanavir [54] in human cancer cells. Phase I clinical trials are underway to evaluate nelfinavir as a potential anticancer agent [56] . As demonstrated for Kaposi's sarcoma [49] , it is possible that protease inhibitors may have an indirect effect through improved immune surveillance for cancer cells or a direct effect on the development of cancer. The proposed mechanism of nelfinavir was the induction of endoplasmic reticulum stress and resulting cell death [52] [53] [54] .
An additional concern regarding cancer risk and antiretroviral use is the recent introduction and use of newer ART classes such as entry, fusion, and integrase inhibitors. It is biologically feasible, for example, that inhibition of these mechanisms may interfere with tumor surveillance. Early trial results suggested the possibility of a higher risk of malignancies in raltegravir-treated [36] or vicriviroc-treated [57] patients against placebo, whereas others have shown no increased malignancy risk for maraviroc-treated patients [58, 59] . Ongoing surveillance for malignancies is needed for these therapies, given the limited use in HIV-infected populations to date.
Immunodeficiency and risk of cancer
As described, the decreased incidence for certain NADMs in the ART era maybe a result of better immune surveillance for malignancy. Prior studies have indicated that individual NADMs associated with immunodeficiency include Hodgkin's lymphoma [2, [60] [61] [62] , lung [60] , penile [60] , lip [60] , testicular [60, 61] , sarcomas [60, 61, 63] , myeloma [61] , and brain [61] , but others have not found this association with NADMs [8, 17, [64] [65] [66] . Many prior studies relied on proximity to the AIDS diagnosis as a marker for immunodeficiency [60, [61] [62] [63] 67] , with few examining the association of CD4 Tcell counts and NADM risk [2, 64] .
AIDS diagnosis
Several recent studies have also reported on the association of a prior AIDS diagnosis [23 ,26 ,27 ,68 ] and the risk of NADMs ( 
Other measures of immune function
Others have provided additional evidence of an association of NADMs and immune status ( Table 3 ). In the Strategies for Management of Anti-Retroviral Therapy (SMART) trial [32 ] , patients enrolled in the CD4 T-cell-guided episodic use of ART study arm had a similar risk of NADMs compared with control patients on continuous ART with a hazard ratio of 1.3 (95% CI 0.7, 2.1), suggesting CD4 T-cell improvements with ART are not strongly associated with NADM risk. A small study in the Women's Interagency HIV Study evaluated the risk of any malignancy (ADM and NADM) and other markers of immune function, including natural killer, natural killer T-cells, and CD8 T-cells. Although baseline markers were not associated with malignancy, current natural killer T-cells were associated with a lower risk (hazard ratio per % higher ¼ 0.7; 95% CI 0. ART, antiretroviral therapy; HR, hazard ratio; IDU, injection drug users; MSM, men who have sex with men; NADM, non-AIDS-defining malignancy; NKT, natural killer T; RCT, randomized clinical trial; RR, risk ratio; SIR, standardized incidence ratio. 
Conclusion
Several NADMs may have a lower risk with use of ART, including liver, breast, colorectal, and lung cancers. In addition, recent studies have indicated that certain individual NADMs appear to be associated with immunosuppression including Hodgkin's lymphoma, oral/pharynx, lung, anal, and colorectal cancers. Thus, continued ART use likely reduces the risk of certain NADMs with improved immune surveillance for malignancy. However, recent studies also indicated that rates of Hodgkin's lymphoma and anal cancer were increased in the ART era, and there has been no change in the risk of lung cancers. Thus, future studies should further characterize the epidemiology of NADMs in HIV-infected persons in the ART era, including changes in the prevalence of risk factors, coinfections, and screening practices in this population.
